Background: The receptor (ER) for estrogen (E2) is routinely assayed as a marker to determine the feasibility of anti-hormone therapy against breast cancer because ER-positive (ER+) tumors are much more likely to respond to anti-hormone therapy than are ER-negative (ER-). However 40% of ER+ breast cancer patients do not respond to anti-hormone therapy. We suggest that this unpredictability of therapeutic responses lies in the current ER assays, which measure only an initial component of the E2-responsive pathway, and that the difference depends upon altered downstream processes. We propose a functional criterion that subclassifies breast cancers on the basis of specific binding of ER to its cognate DNA sequence, the estrogen response element
Introduction
The growth of many breast cancers is affected by hormones, more specifically by estrogen (E2) and progesterone (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . These hormones bind to their protein receptors (ER and PR), which regulate responsive genes via specific protein-DNA interactions (7) (8) (9) (10) . ER and PR are routinely assayed as clinical markers to determine feasibility of applying anti-hormone therapy (11) (12) (13) . Breast cancers measured conventionally are two-thirds ER+, having 100-300 fmol ER/mg of cytosol protein, and one-third ER with normal breast epithelial cells having 0-37 fmol/mg of cytosol protein (14, 15) . Many ER+ cancers are responsive to anti-estrogens such as tamoxifen (TAM) (16) . But 40% of the ER+ tumors do not respond, nor generally do ER- tumors (17) . This may be due to tumor heterogeneity or to mutations that generate ERs whose function is ligand-independent, superfunctional, or bypassed (18) (19) (20) (21) (22) . The ER phenotype is currently defined by either ligand binding or ERspecific antibody assays. ER variants with defective ligand or antibody binding may not be detected by these assays (18, 19) . Therefore, a more informative and simple test for predicting tumor responsiveness to anti-hormone therapy would be valuable. This assay would be important because hormone therapy is the first line of defense if it is applicable (23) .
The action of E2 is initiated with its binding to the hormone-specific receptor (ER), followed by dimerization of ER, phosphorylation, and a change from an inactive to active state (2-7). The dimerized protein interacts with short palindromic DNA sequences designated estrogen response element (ERE), and it activates estrogenresponsive genes (24) . Several other proteins are reported to be involved in both ER-ERE interaction (5, (25) (26) and the downstream event of specific promoter activation (5) (6) (7) 24, (27) (28) (29) (30) . Transcriptional activity of ER is more complex in some cases. It can depend on sequences other than the consensus ERE (31) , and ER even transactivates the brain creatine kinase gene that lacks an ERE, which is apparently mediated by protein-protein interactions involving ER and molecules capable of interacting directly with this promoter (32) . The identification of another class of ER (ER-,B) adds a new dimension to the molecular mechanism of E2-ER pathway transactivation of genes (33, 34) .
An altered functional status of ER in ER+ cells may be due to defects in any one or more of the steps of the multistep ER-response pathway (3 5) . Mutations Electrophoretic Mobility Shift Assay (EMSA) ER-ERE interaction was measured using EMSA by incubating nuclear extracts (40) from cells with 32P-labeled double-stranded synthetic oligonucleotides (shown above) under conditions described by Kumar and Chambon (24) . One nanogram (approximately 30,000 CPM) of 32p_ labeled double-stranded oligonucleotide with palindromic ERE (as shown above) was used per reaction and incubated 30 min at room temperatures. The reaction mixture was then subjected to nondenaturing polyacrylamide gel (6%) electrophoresis (PAGE) and the protein-DNA complex was detected by autoradiography of the dried gel as described previously (41, 42) . ER monoclonal antibodies used were ER-Ab-1, raised against aminoacid residues 120-170 of the N-terminal transactivation domain of calf uterus estrogen receptor; TE 1-1, raised against amino acid residues 300-595 of the C-terminal region of human ER (Neo Markers, Fremont, CA); and SRA 1010, raised against amino acid residues 582-595 of the C-terminal region of human ER (Neo Markers, Fremont, CA); and SRA 1010, raised against amino acid residues 582-595 of the C-terminal region of human ER (Stress Gen, BC, Canada).
Immunofluorescent Staining of Estrogen Receptor
Cells cultured in chamber slides for 24 hr were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde, permeabilized with PBS containing 0.2% Triton X-100, and stained following a standard protocol (43 bExpressed sequence tag (EST) identification is listed for unknown sequence match entries in EST data base.
CA readable DNA sequence is defined as one that has approximately 80% unambiguous bases over a region of at least 100 bases.
dE2 treatment is the same as that described in the legend to Figure 5 . RNA was isolated from each of control and treated samples and subjected to the DD protocol using the specified arbitrary HAP5 and HAP6 and anchor primers of the Gene Hunter DD Kit (45) . Specific DD bands were cut out of the indicated tracks, DNA isolated, PCR amplified, and subjected to direct sequencing.
B A NCBI database using the BLAST algorithm (47) . A match was defined as approximately 96% identity of bases over a stretch of 30 bases. Following database verification of sequences, a single nested 20-mer oligonucleotide was designed that would hybridize to the DD fragment just inside the arbitrary primer site (48 Figure 4A , were used for these experiments. These monoclonal antibodies are all reactive against human ER. Results shown in Figure 4B and C demonstrated interference of DNA-protein complex formation with nuclear extracts from both MCF-7 and 21PT cells in the presence of each of these three ER-specific antibodies, in contrast to a supershift, which suggests blocking of a reaction site (see Discussion). (40) and DNA-protein complex formation was studied by EMSA under binding conditions described by Kumar and Chambon (24) . The reaction mixture in 10 ,ul contained the indicated amounts of proteins and 32P-labeled double-stranded oligonucleotide (30, 000 cpm, 1 ng) and was incubated at room temperature for 30 min. The reaction was terminated by addition of loading dye. The DNA-protein complex was identified as a retarded radioactive band in the nondenaturing PAGE (6%) system as described previously (41, 42) . ER-ERE complex and free 32P-labeled probe are indicated by arrows.
(whole molecule) or in the presence of the antibody raised against an unrelated protein, p50 subunit of NF-KB, did not significantly reduce the intensities of the retarded band (Fig. 4B) (9) . But this ER-ERE interaction in the nuclear extracts from both 21PT (Fig. 5B) and MS (Fig. 5C) 21 PT cells, whereas the intensity of the retarded band representing the ER-ERE complex is much higher in 21PT cells. This suggests a stronger binding affinity of ER to ERE on account of an altered structure of the receptor molecule or the auxiliary binding proteins.
Transactivation of E2-Responsive Genes in MCF-7 and 21PT Cells The activation of most of the E2-responsive genes is a consequence of ER-ERE interaction. The PS2 gene is commonly observed to be overexpressed in breast tumors and is E2 responsive (17) . The PS2 promoter region is well characterized, and it has been established that the palindromic EREs are solely responsible for ER-mediated upregulation of this hormone-responsive gene (36) . We compared transactivation of the PS2 promoter in MCF-7 and 21PT cells by transient transfection of a fusion gene construct, PS2-CAT, to cells grown in the absence or presence of E2, followed by measurement of expression of the reporter CAT gene in cell extracts (24, 42) . This CAT activity was dependent on the concentration of E2 in the growth medium of MCF-7 (ERd+) cells (Fig. 6A) , whereas it was constitutively up-regulated, even in the absence of E2, in 21PT (ER'+) cells (Fig. 6B) . Thus this E2-mediated transactivation pattern strictly correlated with the ER-ERE interactions in these two ER+ breast cancer cell lines as hormone dependent in MCF-7 and hormone independent in 21PT cells.
To substantiate this conclusion we examined the E2-regulated expression of cellular genes by monitoring their levels of expression in MCF-7 and 21PT cells as a function of E2 treatment.
With the mRNA differential display technique (45) we detected at least five genes that were similarly expressed or suppressed in a hormonedependent fashion in MCF-7 cells and in a hormone-independent fashion in 21PT cells (Table 1 ). These results demonstrate that not only that the expression of a transfected gene is hormone dependent or hormone independent in ER+, MCF-7 and 2 1 PT cells, respectively (Fig. 6 ), but also that the expression of five cellular genes show similar patterns of hormone dependency or independency in these two cell lines. Direct se- Figure 3 . Nuclear extracts were prepared, and protein content was measured and subjected to EMSA as described in Figure 3 . (A) The structural and functional domains of ER. The epitope maps of the three ER-antibodies used in this experiment are shown below the sketch, details of the ER-antibodies are described in the Materials and Methods. (B) The influence of ER-Ab-1, mouse IgG, and anti-NF-K-p50 antibody (rabbit polyclonal IgG raised against 15 amino acid residues mapping at the NLS region of NF-KB-p50, mouse, rat, and human reactive, Santa Cruz Biotechnology, Santa Cruz, CA). Binding reaction conditions were the same as described above. The results presented here demonstrate the hormone-dependent or -independent phenotypes of ER that subclassified these cell lines, irrespective of the mechanisms by which they achieved these ER phenotypes. Hormone-dependent downstream functions of E2, ER-ERE interaction, and transactivation of responsive genes were observed only in the presence of the hormone in the ERd+ subclass, thereby suggesting that E2 is essential for the functional state of ER in these cells. Our inability to detect ER-ERE complex formation from the cytoplasm of E2-treated or -untreated cells, and similar observations made previously (9) , could be explained by several mechanisms. These include (1) 2 1PT, are also explained by these properties. That ER is a component of the retarded band in EMSA was established by interactions with anti-ER antibodies. Such antibody-ER interactions with a DNA-protein complex should either generate a larger complex, thereby inducing a supershift, or it can trap ER and make it unavailable for forming the active DNA-binding complex. All the three ER-antibodies tested, irrespective of the epitope map, blocked ER-ERE complex formation as determined by the greatly decreased level of the retarded band in EMSA, thereby establishing the second mechanism. Furlow et al. (54) reported no interference of ER-ERE complex formation by another ER-specific antibody. This discrepancy may be explained by the differences in the experimental conditions, such as use of a purified ER or different antibody, and using the whole plasmid that carries the ERE elements in the binding reaction in contrast to the native receptor and short oligonucleotides that carry the palindromic ERE used in our studies.
A practical outcome of this strategy of determining ER status is its potential for making therapeutic predictions based on the hormone-and anti-hormone-dependent or independent binding of ER to ERE. The management of breast cancer patients involves routine immunohistochemical determination of ER and PR in tumor tissues as prognostic and therapeutic markers. But the current assays cannot accurately predict the outcome of anti-hormone therapy, the first line of defense. To overcome this difficulty we propose a new approach that uses as a criterion for ER status a downstream functional assay of E2 response in breast tumors, one that is beyond the initial interaction of hormone with its specific receptor. The assessment of ER-ERE complex formation, in addition to E2-ER interaction, should identify most of the spectrum of ER variants in breast tumors. These data also provide a strategy for identifying compounds that inhibit ER-ERE complex formation, which can serve as alternative therapy or part of combination therapy for breast tumors that are resistant to antihormones. Future studies using this assay will determine the frequency of the ER'+ subclass of breast tumors.
